Answers are grounded in this paper and cite their sources.
Expert review reveals rising diagnostic biopsy expenses and outdated reimbursement rates across healthcare sectors, highlighting financial strain on hospitals.
Introduction: Lung cancer is still diagnosed at an advanced stage due to lack of early disease symptoms. Areas covered: We have techniques and equipment for rapid on site evaluation of pulmonary lesions. However, with new technology or a combination of technologies in the diagnostic suite the cost of biopsy is rising. Expert opinion: The cost of diagnostic equipment and tools differ between the national health system and private sector. This is due to the economic crisis that our country entered in 2008. The costs for every procedure for lung cancer has not been updated for more than 15 years, and therefore in several cases the reimbursement for the hospitals is lower for both national and private sector.
No takes yet. Share an insight, caveat, or question.
Zarogoulidis et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: